Диссертация (1141138), страница 21
Текст из файла (страница 21)
J. Carrillo-Muсoz, C. Tur-Tur, G. Giusianoet al. // Expert. Rev. Anti. Infect. Ther. – 2013. – Vol. 11. – P. 347-358.225. Carrilo-Muñoz, A. J. In-vitro antifungal activity of sertaconazole, bifonazole,ketoconazole, and miconazole against yeasts of the Candida genus / A. J.Carrilo-Muñoz, C. Tur, J. Torres // J. Antimicrob. Chemother.
– 1996. – Vol. 37.–4. – P. 815-819.226. Cheng, S. A prospective epidemiological study on tinea pedis andonychomycosis in Hong Kong / S. Cheng, L. Chong // Chinese med. journal. –2002. – Vol. 115. – № 6. – P. 860-865.227. Chi, C. C. The causative pathogens of onychomycosis in southern Taiwan / C. C.Chi, S. H. Wang, M. C. Chou // Mycoses. – 2005.
– Vol. 48. – № 6. – P. 413420.136228. Choudhary, S.V. Efficacy and Safety of Terbinafine Hydrochloride 1% Creamvs. Sertaconazole Nitrate 2% Cream in Tinea Corporis and Tinea Cruris: AComparative Therapeutic Trial / S. V. Choudhary, S. Bisati, A. L. Singh, S.Koley // Indian J. Dermatol. – 2013. – Vol. 58. – № 6. – P. 457-460.229.
Cojocaru,I.ConsiderationsaproposdePincidencedecertainesdermatomycoses chez des maladies de different groups d’ages / I. Cojocaru, L.Dulgheru // Mycosen. – Barcelona, Spain. – 1986. – Vol. 30. – P. 434-439.230. Croxtall, J. D. Sertaconazole: a review of its use in the management of superficial mycoses in dermatology and gynecology / J.
D. Croxtall, G. L. Plosker //Drugs. – 2009. – Vol. 69. – № 3. – P. 339-359.231. da Silva, B. C. M. Dermatophytosis and immunovirological status ofHIV‐infected and AIDS patients from Sao Paulo city, Brazil / B. C. M. da Silva,C. R. Paula, M. E. Auler, L. D. S. Ruiz, J. I. dos Santos, M. C. N.
Yoshioka //Mycoses. – 2014. – № 1. – P. 371-376.232. de Chauvin, M. F. Исследование по изучению деконтаминации стелек, колонизированных Trichophyton rubrum: эффект 1% порошка спрея тербинафина и 1% раствора спрея тербинафина / M. F.
de Chauvin // Українськийжурнал дерматології, венерології, косметології. – 2012. – Vol. 44. – № 1. – P.111-116.233. Del Rosso, J. Q. Comprehensive management of patients with superficial fungalinfections: the role of sertaconazole nitrate / J. Q. Del Rosso // Cutis. – 2008. –Vol. 81. – №.
6. – P. 4-18.234. Dogra, S. Epidemiology of onychomycosis patients with diabetes mellitus in India / S. Dogra, В. Kumar, A. Bhansoli, A. Chacrabarty // Int. J. Dermatol. –2002. – Vol. 41. – № 10. – P. 647-651.235. Dorko, E. Epidemiology and prevalence of onychomycosis / E. Dorko, J. B.Jautova, H. S. Zeienkova // Ann. Dermatol. Venerol. – 2002. – Vol. 129.
– P.661.137236. Dorko, E. The frequency of Candida species in onychomycosis / E. Dorko, J.Jautova, L. Tkáčiková, A. Wantrubova // Folia microbiologica. – 2002. – Vol.47. – № 6. – P. 727-731.237. Drohuet, E. In vitro Antfungal Activity of Sertaconazole / E. Drohuet, B. Dupon// Arznelm. Forsch. Drug Res. – 1992. – Vol. 42. – № 5a.
– P. 705-710.238. Elewski, B. E. Onychomycosis: Pathogenesis, Diagnosis, and Management / B.E. Elewski // Clinical Microbiology Reviews. – 1998. – Vol. 11. – № 3. – P.415-429.239. Elewski, B. E. Prevalence of onychomycosis: highlights of third annual international summit on cutaneous antifungal therapy / B. E.
Elewski, M. A. Charif //Clin. Infect. Dis. – 1997. – Vol. 23. – P. 305-313.240. Elewski, B. E. Safe and effective treatment of seborrheic dermatitis / B. E.Elewski // Cutis. – 2009. – Vol. 83. – P. 333-338.241. Elewski, B. International summit on cutaneous antifungal therapy: Boston, Massachusetts, Nov. 11–13, 1994 // B. Elewski, R. J. Hay // Journal of the AmericanAcademy of Dermatology. – 1995. – Vol.
33. – № 5. – P. 816-822.242. Erbagci, Z. A prospective epidemiological survey on the prevalence ofonychomycosis and depmatophytosis in male boarding school residents / Z.Erbagci, A. Tuncel, Y. Zer et al // Mycopathologia. – 2005. – Vol. 159. – P. 347.243. Escobar, M. L. Onychomycosis por hongos ambientales no dermatofiticos / M.L. Escobar, J. Carmona-Fonseca // Rev. Iberoam Micol. – 2003. – Vol. 20. – P.6-10.244. Esso, D.
V. Залаин (сертаконазол) в лечении детей с дерматофитиями кожи/ D. V. Esso, G. Fajo, I. Losada, M. Vflattonga, J. M. Casanovas, J. Clanxet, A.Aliaga // Clinical therapeutics. – 1995. – Vol. 17. – № 2. – P. 1-4.245. Evans, E. G. Nail dermatophytosis: the nature and scale of the problem / E.
G.Evans // J. Derm. Treatment. – 1990. – Vol. 1. – P. 47-48.246. Faergemann, J. Epidemiology, clinical presentation and diagnosis ofonychomycosis / J. Faergemann, R. Baran // Br. J. Dermatol. – 2004. – Vol. 149.– № 65. – P. 1-4.138247. Farre, M. Pharmacokineticsand tolerance of sertaconazole in man after repeatedpercutaneous administration / M. Farre, B.
Ugena, J. M. Badenas et al. //Arzneimittelforschung. – 1992. – Vol. 42. – P. 752-754.248. Fonseca, E. Evaluación de la eficacia y seguridad de Sertaconazol en crema enaplicación única diaria en el tratamiento de las dermatomicosis / E. Fonseca, J.Del Pozo, M. Márquez // Piel. – 1997. – Vol. 12. – P. 183-8.249. Ghaninejad, H. Sertaconazole 2% cream vs. miconazole 2% cream for cutaneous mycoses: a double-blind clinical trial / H. Ghaninejad, K. Gholami, P.Hashemi, M. Hajibabai, Z.
Rahbar, M. S. Farivar, F. Mastani, A. Rashidi // Clin.Exp. Dermatol. – 2009. – Vol. 34. – № 8. – P. 837-9.250. Ghannoum, M. A. Molecular analysis of dermatophytes suggests spresd of infection among household members / M. A. Ghannoum, P. K. Mukherjee, E. M.Warshaw et.
al. // Cutis. – 2013. – Vol. 91. – P. 237-45.251. Ghannoum, M. Azole resistance in Dermatophytes: prevalence and mechanismof action // M. Ghannoum // J. Am. Podiat. Med. Assoc. – 2016. – Vol. 106. –№ 1. – P. 79-86.252. Gill, D. A review of the epidemiology of tinea unguinum in the community / D.Gill, R. Marks // Austral. J. Dermatol. – 1999.
– Vol. 40. – № 1. – P. 6-13.253. Gil-Lamaignere, C. Differential effects of the combination of caspofungin andterbinafine against Candida albicans, Candida dubliniensis and Candida kefyr /C. Gil-Lamaignere, F. M. Muller // Int. J. Antimicrob. Agents. – 2004. – Vol. 23.– P. 520-3.254. Goldust, M. Double blind study of sertaconazole 2% cream vs.
clotromazole 1%cream in treatment of seborrheic dermatitis / M. Goldust, E. Rezaee, S. Rouhani// Annals of Parasitolog. – 2013. – Vol. 59. – № 1. – P. 25-29.255. Guarro, J. Alterations produced by sertaconazole on the morphology and ultrastructure of Candida albicans / J. Guarro, M. J. Figueras, J. Cano // Mycoses. –1989. – Vol. 32. – № 6.
– P. 283-95.139256. Gunduz, T. Onychomycosis in primary school children: association with socioeconomic conditions / T. Gunduz, D. Y. Metin, T. Sacar et al. // Mycoses. –2006. – Vol. 49. – № 5. – P. 431-433.257. Gupta, A. K. How to improve cure rates the management of onychomycosis / A.K.
Gupta, J. E. Ryder // Dermatol. Clin. – 2003. – Vol. 21. – P. 499-505.258. Gupta, A. K. Prevalence and epidemiology of toenail onychomycosis in diabeticsubject: a multicentre survey / A. K. Gupta, N. Konnikov, P. MacDonald // Br. J.Dermatol.
– 1998. – Vol. 139. – № 4. – P. 665-671.259. Gupta, A.K. Non-dermatophyte onychomycosis / A.K. Gupta // J. Dermatol.Clin. – 2003. – Vol. 21. – № 2. – P. 257-268.260. Gut, J. Direct membrane damaging effect of Sertaconazole on Candida albicansas a mechanism of its fungicidal activity / J. Gut et al. // Arzneim. Forsch. DrugRes. – 1992. – Vol.
42. – P. 721-724.261. Hagedom, M. Double-blind, randomizld, parallel group, multlcenter study toevaluate the efficacy and safety Setaconazole compared to Clotrimazole inpatiets with dermatomycoses / M. Hagedom // Report on file.262. Hainer, B. L. Dermatophyte infections / B.L. Hainer // Am. Fam. Physician. –2003. – Vol.
67. – P. 101-108.263. Haneke, E. Achilles foot-screening project: background, objectives and design /E. Haneke //J. Europ. Acad. Dermatol.Venereol. – 1999. – Vol. 12. – Р. 2-5.264. Haneke, E. The scope of onychomycosis: epidemiology and clinical features / E.Haneke // Int. J. Dermatol. – 1999. – Vol. 38. – № l-2. – P. 7-12.265. Havlickova, B. Epidemiological trends in skin mycoses Worldwide / B.Havlickova, V. A. Czaika, M. Friedrich // Mycosis.
– 2008. – Vol. 51. – № 4. –Р. 2-15.266. Hekkila, H. The prevalens of onychomycosis in Finland / H. Hekkila, S. Stubb //Br. J. Dermatol. – 1995. – Vol. 24. – № 5. – P. 699-703.267. Hirschmann, J. V. Pustular tinea pedis / J. V. Hirschmann, G. I. Raugi // J. Amer.Acad. Dermatol. – 2000. – Vol. 42. – P. 132-133.140268. Ilkit, M.
Onychomycosis in Adana, Turkey: a 5-year study / M. Ilkit // Int. J.Dermatol. – 2005. – Vol. 44. – № 10. – P. 851-854.269. Ilkit, M. Tinea pedis: The etiology and global epidemiology of a common fungalinfection / M. Ilkit, M. Durdu // Critical reviews in microbiology. – 2014. – № 0.– P. 1-15.270. Jerajani, H. Comparative assessment of the efficacy and safety of sertaconazole(2%) cream versus terbinafine cream (1%) versus luliconazole (1%) cream inpatients with dermatophytoses: a pilot study / H. Jerajani, C. Janaki, S. Kumar,M. Phiske // Indian J. Dermatol. – 2013. – Vol.
58. – № 1. – P. 34-38.271. Kacar, N. The prevalence aetiological agents and therapy of onychomycosis inpatients with psoriasis: a prospective controlled trial / N. Kacar, S. Ergin, C.Ergin et al. // Clin. Exp. Dermatol. – 2006. – № 4. – P. 19-21.272. Kircik, L. Observational evaluation of sertaconazole nitrate cream 2% in thetreatment of pruritus related to tinea pedis / L. Kircik // Cutis. – 2009. – Vol. 84.– P. 279-83.273. Klein, N.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
